Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer (Q37875054)

24 August 2017

1 reference

title

Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer (English)

1 reference

24 August 2017

Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer (English)

1 reference

https://api.crossref.org/works/10.2165/11585500-000000000-00000

2 December 2024

Ramon Salazar

1 reference

24 August 2017

Diane Reidy-Lagunes

series ordinal

1 reference

24 August 2017

James Yao

series ordinal

1 reference

24 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21568362

2 December 2024

publication date

1 May 2011

1 reference

24 August 2017

7 May 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21568362

2 December 2024

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

841-852

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

mTOR signalling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

The pathophysiological consequences of somatostatin receptor internalization and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Expression of vascular endothelial growth factor in growth hormone-secreting pituitary adenomas: special reference to the octreotide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Metastatic carcinoid tumor: changing patterns of care over two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Pituitary-independent effect of octreotide on IGF1 generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Emerging drugs for the treatment of metastatic renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Targeted agents: the rules of combination

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Targeting the RAF-MEK-ERK pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11585500-000000000-00000

Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features

21 January 2018

1 reference

12 December 2020

Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?

1 reference

12 December 2020

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

1 reference

12 December 2020

Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression

1 reference

12 December 2020

1 reference

12 December 2020

Somatostatin receptor imaging: predictive and prognostic considerations

1 reference

12 December 2020

Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I.

1 reference

12 December 2020

Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells

1 reference

12 December 2020

Journal of Clinical Oncology

582s

Hörsch

2007

1 reference

https://api.crossref.org/works/10.2165/11585500-000000000-00000

Journal of Clinical Oncology

2 December 2024

15s

Yao

2010

1 reference

https://api.crossref.org/works/10.2165/11585500-000000000-00000

2 December 2024

Identifiers

1 reference

Dimensions Publication ID

24 August 2017

1021851010

0 references

1 reference